CGRP receptor antagonists

US8748429B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Guanglin Luo · Newtown, US
• Gene M. Dubowchik · Middlefield, US
• John E. Macor · Guilford, US
• Ling Chen · Shanghai, CN

Key dates

• Filing date: Apr 4, 2012
• Grant date: Jun 10, 2014
• Expiry date: May 28, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).